Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience - Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Jacques Delaunay, Anne Banos, Michel Blanc, Norbert Vey, Aline Schmidt, Sorin Visanica, Virginie Eclache, Pascal Turlure, Odile Beyne-Rauzy, Agnès Guerci - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Leukemia Research, 11(35), p. 1444-1448, 2011

DOI: 10.1016/j.leukres.2011.05.034

Links

Tools

Export citation

Search in Google Scholar

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Journal article published in 2011 by Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Jacques Delaunay, Anne Banos, Michel Blanc, Norbert Vey, Aline Schmidt, Sorin Visanica, Virginie Eclache, Pascal Turlure, Odile Beyne-Rauzy, Agnès Guerci and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO